Sufentanil-ratiopharm may be available in the countries listed below.
Sufentanil citrate (a derivative of Sufentanil) is reported as an ingredient of Sufentanil-ratiopharm in the following countries:
International Drug Name Search
Apo-Nizatidine may be available in the countries listed below.
Nizatidine is reported as an ingredient of Apo-Nizatidine in the following countries:
International Drug Name Search
Atock may be available in the countries listed below.
Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Atock in the following countries:
International Drug Name Search
Drug Facts
Guaifenesin 1200 mg
Expectorant
helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Do not use
Ask a doctor before use if you have
Stop use and ask a doctor if
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
carbomer 934P, NF; FD&C blue #1 aluminum lake; hypromellose, USP; magnesium stearate, NF; microcrystalline cellulose, NF; sodium starch glycolate, NF
1-866-MUCINEX (1-866-682-4639) You may also report side effects to this phone number.
Dist. by: Reckitt Benckiser Inc.
Parsippany, NJ 07054-0224
MAXIMUM STRENGTH
NDC 63824-023-36
Mucinex®
1200 mg guaifenesin extended-release bi-layer tablets
EXPECTORANT
12
HOUR
28 EXTENDED-RELEASE BI-LAYER TABLETS
| MUCINEX MAXIMUM STRENGTH guaifenesin tablet, extended release | ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA021282 | 08/11/2009 | |
| Labeler - Reckitt Benckiser, Inc. (094405024) |
Temporarily relieving cough due to the common cold, upper respiratory tract infections, sinus inflammation, sore throat, or bronchitis.
Dextromethorphan/Guaifenesin Extended-Release Tablets are a combination of an expectorant (guaifenesin) and a cough suppressant (dextromethorphan). It works by loosening mucus and lung secretions in the chest and making coughs more productive.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Dextromethorphan/Guaifenesin Extended-Release Tablets. Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Dextromethorphan/Guaifenesin Extended-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Dextromethorphan/Guaifenesin Extended-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Dextromethorphan/Guaifenesin Extended-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Dextromethorphan/Guaifenesin Extended-Release Tablets.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness; drowsiness; stomach upset.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Dextromethorphan/Guaifenesin side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; excitement; hallucinations; slowed breathing.
Store Dextromethorphan/Guaifenesin Extended-Release Tablets at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dextromethorphan/Guaifenesin Extended-Release Tablets out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Dextromethorphan/Guaifenesin Extended-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
See also: Generic Humalog, Generic Humalog Pen
Humalog KwikPen is a brand name of insulin lispro, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Humalog KwikPen available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog KwikPen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Humalog KwikPen.
Zeptol may be available in the countries listed below.
Carbamazepine is reported as an ingredient of Zeptol in the following countries:
International Drug Name Search
Cefdox may be available in the countries listed below.
Cefpodoxime proxetil (a derivative of Cefpodoxime) is reported as an ingredient of Cefdox in the following countries:
International Drug Name Search
Softening, loosening, and removing excessive earwax.
Debrox Solution is a form of peroxide. It works by softening and removing earwax.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Debrox Solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Debrox Solution. Because little, if any, of Debrox Solution is absorbed into the blood, the risk of it interacting with another medicine is low.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Debrox Solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Debrox Solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Debrox Solution.
All medicines may cause side effects, but many people have no, or minor, side effects. When used in small doses, no COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Debrox side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Debrox Solution at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Debrox Solution out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Debrox Solution. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: Dantrolene Sodium
Class: Direct-acting Skeletal Muscle Relaxants
VA Class: MS200
CAS Number: 24868-20-0
Risk of developing potentially fatal, hepatic injury (e.g., hepatitis); should not be used for unlabeled indications.109
Females, patients >35 years of age, and those receiving other drugs (especially estrogens) concomitantly are at greatest risk.109
Risk of symptomatic hepatitis (fatal and nonfatal) may be dose dependent; incidence much higher at dosages ≥800 mg daily than at dosages ≤400 mg daily.109 Even intermittent, short courses at higher dosages associated with increased risk.109 Use lowest possible effective dose.109
Overt hepatitis most frequently observed between 3rd and 12th month of therapy.109
Frequently monitor hepatic function.109 (See Hepatic Effects under Cautions.)
If benefits are not evident within 45 days, discontinue therapy.109
Skeletal muscle relaxant.108 109
Oral management of spasticity resulting from upper motor neuron disorders (e.g., multiple sclerosis, cerebral palsy, spinal cord injury, stroke syndrome).109
Ineffective in the treatment of amyotrophic lateral sclerosis (ALS).a
Not indicated for the treatment of muscle spasms resulting from rheumatic disorders or musculoskeletal trauma.109 a
IV treatment of fulminant hypermetabolism of skeletal muscle that is characteristic of malignant hyperthermia crisis;108 should be used with and not as a substitute for supportive measures.a
Preoperative and postoperative prevention or attenuation of malignant hyperthermia in susceptible individuals; used orally or IV (when oral therapy is not practical or feasible).108 109
Has been used for the treatment of neuroleptic malignant syndrome†; fatalities reported despite therapy with the drug.108 109
Establish therapeutic goal before initiating therapy.109 Use lowest possible effective dosage.109 Discontinue drug if beneficial effects are not attained within 45 days.109 (See Boxed Warning.)
Subjective impressions of improvement may sometimes be confirmed by withdrawal of the drug for 2–4 days.109
Immediately discontinue all anesthetic agents and institute IV dantrolene as soon as malignant hyperthermia crisis is recognized.108
Monitor vital signs; employ the usual precautions associated with surgery in susceptible patients, since malignant hyperthermia may only be attenuated rather than prevented.108
Administer orally or by continuous IV infusion or rapid IV injection.108 109
Administer orally 1–4 times daily.109
To prepare oral suspension containing 25 mg of dantrolene sodium per 5 mL, empty 5 100-mg capsules in 50 mL of Syrup NF, then add a solution containing 150 mg of citric acid in 10 mL of water followed by a sufficient volume of Syrup NF to make 100 mL.c Mix thoroughly before use.c
For solution compatibility information, see Compatibility under Stability.
For IV infusion, transfer reconstituted solution from the appropriate number of vials to plastic infusion bag.109 Do not use large glass containers; precipitate formation observed with some glass containers.108
Avoid extravasation (injection has high pH).108
Add 60 mL of sterile water for injection (without bacteriostatic agent) to vial containing 20 mg of dantrolene sodium.108 Shake vial until solution is clear.108
Although reconstituted solutions are stable for 6 hours,108 infusions preferably should be prepared immediately before use.a
Preoperative prophylaxis: Infuse IV over approximately 1 hour beginning about 1.25 hours before anticipated anesthesia.108
Treatment of malignant hyperthermia syndrome: Rapid IV injection.108
Available as dantrolene sodium; dosage expressed in terms of the salt.108 109
Children ≥5 years of age: 0.5 mg/kg once daily for 7 days, followed by 0.5 mg/kg 3 times daily for 7 days, then 1 mg/kg 3 times daily for 7 days, and then 2 mg/kg 3 times daily, if necessary.109 Some patients may require doses 4 times daily.109
If no additional benefit is observed at the next higher dosage, decrease dosage to the previous (lower) dosage.109
4–8 mg/kg daily in 3 or 4 divided doses for 1–2 days prior to surgery; give the last dose approximately 3–4 hours before surgery with small amount of water.109
2.5 mg/kg infused over approximately 1 hour beginning about 1.25 hours before anticipated anesthesia; may give additional individualized doses intraoperatively, if necessary.108
Initially, 1 mg/kg or more by rapid IV injection.108 Repeat dose as necessary until physiologic and metabolic abnormalities subside or a maximum total dosage of 10 mg/kg is reached.108
Average total dosage: 2.5 mg/kg.a
Repeat regimen if physiologic and metabolic abnormalities reappear.108
4–8 mg/kg daily in 4 divided doses for up to 3 days after the crisis.109
Initially, 1 mg/kg or more as clinically indicated.108 Individualize subsequent doses.108
Initially, 25 mg once daily for 7 days, followed by 25 mg 3 times daily for 7 days, then 50 mg 3 times daily for 7 days, and then 100 mg 3 times daily, if necessary.109 Some patients may require doses 4 times daily.109
If no additional benefit is observed at the next higher dosage, decrease dosage to the previous (lower) dosage.109
4–8 mg/kg daily in 3 or 4 divided doses for 1–2 days prior to surgery; give the last dose approximately 3–4 hours before surgery with small amount of water.109
2.5 mg/kg infused over approximately 1 hour beginning about 1.25 hours before anticipated anesthesia; may give additional individualized doses intraoperatively, if necessary.108
Initially, 1 mg/kg or more by rapid IV injection.108 Repeat dose as necessary until physiologic and metabolic abnormalities subside or a maximum total dosage of 10 mg/kg is reached.108
Average total dosage: 2.5 mg/kg.a
Repeat regimen if physiologic and metabolic abnormalities reappear.108
4–8 mg/kg daily in 4 divided doses for up to 3 days after the crisis.109
Initially, 1 mg/kg or more as clinically indicated.108 Individualize subsequent doses.108
Maximum 100 mg 4 times daily.109
Maximum 10 mg/kg.108
Maximum 100 mg 4 times daily.109
Maximum 10 mg/kg.108
Oral dantrolene contraindicated in patients with active hepatic disease (e.g., hepatitis, cirrhosis).109
Also contraindicated in patients who must utilize spasticity to maintain upright posture and balance in moving or to obtain or maintain increased body function.109
No contraindications to IV dantrolene for prophylaxis or management of malignant hyperthermia crisis.108
Fatal and nonfatal hepatic disorders of idiosyncratic or hypersensitivity type possible with oral dantrolene.108 109 (See Boxed Warning.)
Obtain serum AST, ALT, alkaline phosphatase, and total bilirubin concentrations prior to and periodically during therapy or whenever symptoms of hepatitis occur.109
If liver function test abnormalities occur alone, consider discontinuing therapy; continue or reinstitute the drug only if major benefits occurred during dantrolene therapy.109
If symptoms of hepatitis are accompanied by liver function test abnormalities or jaundice, discontinue dantrolene.109
Following discontinuance for clinical and/or laboratory evidence of hepatotoxicity, reinstitute dantrolene only in patients who clearly need the drug and only after symptoms and laboratory abnormalities of hepatotoxicity have resolved.109 Hospitalize patient to reinitiate therapy with very small doses; gradually increase dosage with frequent monitoring of liver function; discontinue drug immediately if signs of liver abnormality recur.109
Long-term safety in humans yet to be established.109
Nephropathy, benign and malignant mammary and testicular tumors, hepatic lymphangiomas, and hepatic angiosarcomas reported following long-term use in animals; assess risk/benefits of chronic administration.109
Possible photosensitivity reactions; limit exposure to sunlight.109
Performance of activities requiring mental alertness may be impaired.108 109
Concurrent use of other CNS depressants may potentiate CNS depression.108 109 (See Specific Drugs under Interactions.)
If mannitol is used for the prevention or treatment of late renal complications of malignant hyperthermia, consider mannitol in the IV dantrolene formulation (3 g of mannitol per 20-mg vial) as part of the total amount administered.108
Use with caution in patients with severe cardiac impairment secondary to myocardial disease or with impaired pulmonary function (particularly obstructive pulmonary disease).109
Category C.108 109
Readily crosses the placenta.108 (See Distribution under Pharmacokinetics.)
Distributed into milk;b use of oral dantrolene not recommended.109
Long-term safety of oral dantrolene not established in children <5 years of age.109
Weigh possible risks against potential benefits before initiating long-term oral therapy; adverse effects may become evident only after many years.109
Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.108
Titrate dosage carefully.108
Use with caution in patients with a history of hepatic impairment.109
Muscle weakness, drowsiness, dizziness, lightheadedness, diarrhea, nausea, malaise, fatigue.a 109
Metabolized in the liver, but the precise enzymes responsible are unknown.108
Pharmacokinetic interaction with CYP enzyme inducers theoretically possible.108
Drug | Interaction | Comment |
|---|---|---|
Calcium-channel blockers (e.g., verapamil) | Cardiovascular collapse reported rarely108 | Concomitant use during malignant hyperthermia crisis not recommended108 |
Clofibrate | Decreased binding of dantrolene to plasma proteins108 | |
CNS depressants | Possible additive CNS effects (e.g., dizziness)108 109 | Use with caution108 109 |
Diazepam | Additive sedative effect; dantrolene metabolism and protein binding unaffacted108 | Use with cautiona |
Estrogens | Possible increased frequency of hepatotoxicity in women >35 years of age109 | Potential for interaction not clearly established; use with caution109 |
Phenobarbital | Pharmacokinetic interaction unlikely; dantrolene metabolism unaffected108 | |
Phenytoin | No change in binding of dantrolene to plasma proteins108 | |
Tolbutamide | Increased binding of dantrolene to plasma proteins108 | |
Vecuronium | Potentiation of vecuronium-induced neuromuscular blockade108 | |
Warfarin | Decreased binding of dantrolene to plasma proteins108 |
Absorption following oral administration is incomplete and slow but consistent.109
Readily crosses the placenta, with maternal and fetal whole blood concentrations approximately equal at delivery; neonatal concentrations then fall approximately 50% per day for 2 days before declining sharply.108
Substantially bound to plasma proteins (mostly albumin); binding is readily reversible.108
Specific metabolic pathways not established.108 May undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.108
Specific pathways not established.108
Approximately 4–8 hours following IV administration.108
Approximately 9 hours following oral administration in adults.109
<40°C.109
15–30°C.108 Avoid prolonged exposure to light.108
Store reconstituted solutions at 15–30°C for up to 6 hours.108 Protect from light.108
For information on systemic interactions resulting from concomitant use, see Interactions.
Incompatible |
|---|
Dextrose 5% in water |
Sodium chloride 0.9% |
Causes skeletal muscle relaxation through a direct effect on skeletal muscle, probably by interfering with release of calcium from the sarcoplasmic reticulum.108 109
Interference with calcium release from the sarcoplasmic reticulum may prevent the increase in myoplasmic calcium that activates acute catabolism of skeletal muscle cells in patients with anesthesia-induced malignant hyperthermia.108
Has little or no effect on the contraction of cardiac or intestinal smooth muscle, except possibly at concentrations higher than those required for effects on skeletal muscle contraction.a
Risk of hepatoxicity with oral dantrolene.108 109
Risk of dizziness and muscle weakness; use caution when driving or operating machinery.108 109 Do not drive or operate machinery within 48 hours of receiving IV dantrolene.109
Risk of choking and difficulty swallowing; exercise caution during meals.108
Risk of photosensitivity reactions; limit exposure to sunlight.109
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.108 109
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, alcohol consumption, and any concomitant illnesses.108 109
Importance of informing patients of other important precautionary information.108 109 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Capsules | 25 mg* | Dantrium | Procter & Gamble |
Dantrolene Sodium Capsules | Amide, Global | |||
50 mg* | Dantrium | Procter & Gamble | ||
Dantrolene Sodium Capsules | Amide, Global | |||
100 mg* | Dantrium | Procter & Gamble | ||
Dantrolene Sodium Capsules | Amide, Global | |||
Parenteral | For injection | 20 mg | Dantrium Intravenous (with mannitol 3 g) | Procter & Gamble |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Dantrium 100MG Capsules (JHP PHARMACEUTICALS): 45/$99.99 or 135/$291.99
Dantrium 25MG Capsules (JHP PHARMACEUTICALS): 45/$58.98 or 135/$164.96
Dantrium 50MG Capsules (JHP PHARMACEUTICALS): 45/$81.99 or 135/$234.97
Dantrolene Sodium 100MG Capsules (GLOBAL PHARMACEUTICAL CORP): 45/$76.99 or 135/$219.97
Dantrolene Sodium 25MG Capsules (GLOBAL PHARMACEUTICAL CORP): 30/$34.99 or 90/$81.97
Dantrolene Sodium 50MG Capsules (GLOBAL PHARMACEUTICAL CORP): 45/$63.99 or 135/$175.97
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions July 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
Only references cited for selected revisions after 1984 are available electronically.
100. Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatry. 1982; 139:944-5. [IDIS 154797] [PubMed 6124135]
101. Goekoop JG, Carbaat PAT. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet. 1982; 2:49-50.
102. May DC, Morris SW, Stewart RM et al. Neuroleptic malignant syndrome: response to dantrolene sodium. Ann Intern Med. 1983; 98:183-4. [IDIS 164929] [PubMed 6824251]
103. Daoudal P, Delacour JL. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet. 1982; 2:217. [PubMed 6123917]
104. Granato JE, Stern BJ, Ringel A et al. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Ann Neurol. 1983; 14:89-90. [IDIS 173103] [PubMed 6614876]
105. Goulon M, de Rohan-Chabot P, Elkharrat D et al. Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of the two cases. Neurology. 1983; 33:516-8. [IDIS 169146] [PubMed 6682201]
106. Rappaport PL. Extemporaneous dosage preparations for pediatrics. Can J Hosp Pharm. 1983; 36:66-70,74. [PubMed 10262678]
107. Kaplan RF, Feinglass NG, Webster W et al. Phenelzine overdose treated with dantrolene sodium. JAMA. 1986; 255:642-4. [IDIS 210184] [PubMed 3944965]
108. Procter & Gamble Pharmaceuticals. Dantrium IV (dantrolene sodium) for injection prescribing information. Cincinnati, OH; 2001 May.
109. Procter & Gamble Pharmaceuticals. Dantrium (dantrolene sodium) capsules prescribing information. Cincinnati, OH; 1997 Feb.
110. Rubin AS, Zablocki AD. Hyperkalemia, verapamil, and dantrolene. Anesthesiology. 1987; 66:246-9. [IDIS 227329] [PubMed 3813090]
111. Dantrolene (Dantrium) interactions: verapamil (e.g., Calan). In: Hansten PD, Horn JR. Hansten and Horn’s drug interactions, analysis and managements. St. Louis, MO. Facts and Comparisons; 2002:450a.
a. AHFS drug information 2003. McEvoy GK, ed. Dantrolene. Bethesda, MD: American Society of Health-System Pharmacists; 2003:1321-5.
b. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and lactation. 6th ed. Baltimore, MD: Williams & Wilkins; 2002:364-6.
c. Nahata MC, Hipple TF. Pediatric drug formulations. 4th ed. Cincinnati, Ohio: Harvey Whitney Books Company; 2000: 35.
da-PIP-ra-zole
In the U.S.
Available Dosage Forms:
Therapeutic Class: Ophthalmologic Agent
Pharmacologic Class: Alpha-Adrenergic Blocker
Dapiprazole is used in the eye to reduce the size of the pupil after certain kinds of eye examinations.
Some eye examinations are best done when your pupil (the black center of the colored part of your eye) is very large, so the doctor can see into your eye better. dapiprazole helps to reduce the size of your pupil back to its normal size after the eye examination.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For dapiprazole, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to dapiprazole or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Studies on dapiprazole have been done only in adult patients, and there is no specific information comparing use of dapiprazole in children with use in other age groups.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing use of dapiprazole in the elderly with use in other age groups, dapiprazole is not expected to cause different side effects or problems in older people than it does in younger adults.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | B | Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of dapiprazole. Make sure you tell your doctor if you have any other medical problems, especially:
The dose of dapiprazole will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of dapiprazole. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Even after using dapiprazole, you may have blurred vision or other vision problems. If any of these occur, do not drive, use machines, or do anything else that could be dangerous if you are not able to see well.
dapiprazole may cause your eyes to become more sensitive to light than they are normally. Wearing sunglasses and avoiding too much exposure to bright light may help lessen the discomfort.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: dapiprazole Ophthalmic side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Relieving symptoms of sinus congestion, sinus pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Deconamine SR Controlled-Release Capsules are an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, relieving congestion and pressure.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Deconamine SR Controlled-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Deconamine SR Controlled-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Deconamine SR Controlled-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Deconamine SR Controlled-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Deconamine SR Controlled-Release Capsules.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Deconamine SR side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Deconamine SR Controlled-Release Capsules at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Deconamine SR Controlled-Release Capsules out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Deconamine SR Controlled-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Darvon Compound-65 should not be used by people who are suicidal or who easily become addicted to medicines, alcohol, or other substances. Do not take more of Darvon Compound-65 than the dose your doctor prescribed. Taking excessive doses of Darvon Compound-65 by itself, with other medicines, or with alcohol may cause serious side effects and could be fatal. Limit the amount of alcohol you drink while you are taking Darvon Compound-65. Tell your doctor if you have a history of any substance abuse, mood or mental disorders, suicidal thoughts or attempts, or if you take any medicines that cause drowsiness such as tranquilizers, sleep medicines, muscle relaxers, or antidepressants.
Relieving mild to moderate pain with or without fever.
Darvon Compound-65 is a combination narcotic analgesic, caffeine, and salicylate. The narcotic analgesic works in the brain to decrease pain. The salicylate and caffeine help to increase the pain relief.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Darvon Compound-65. Tell your health care provider if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Darvon Compound-65. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Darvon Compound-65 may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Darvon Compound-65 as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Darvon Compound-65.
When used for long periods of time or at high doses, Darvon Compound-65 may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Darvon Compound-65 stops working well. Do not take more than prescribed.
Darvon Compound-65 can cause DEPENDENCE if taken in higher doses than recommended by your health care provider or over a long period of time. Take Darvon Compound-65 exactly as prescribed by your health care provider. If you suddenly stop taking Darvon Compound-65, you may experience WITHDRAWAL symptoms including anxiety; diarrhea; fever, runny nose, or sneezing; goosebumps and abnormal skin sensations; nausea; pain; rapid heartbeat; rigid muscles; seeing, hearing, or feeling things that are not there; shivering or tremors; sweating; trouble sleeping; and vomiting.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; dizziness; drowsiness; lightheadedness; nausea; vomiting.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); anxiety; black or bloody stools; cold or clammy skin; confusion; decreased urination; excessive sweating; hallucinations; hearing loss; loss of appetite; loss of consciousness; mental or mood changes; ringing in the ears; seizures; severe drowsiness or dizziness; severe or persistent stomach pain or heartburn; unusual bruising or bleeding; vision changes; vomit that looks like coffee grounds; weakness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Darvon Compound-65 side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include anxiety; confusion; dilated pupils; fast or irregular heartbeat; increased sweating; muscle pain; ringing in the ears; severe or persistent drowsiness, dizziness, nausea, or vomiting; slow or difficult breathing; weakness.
Store Darvon Compound-65 at room temperature, between 68 and 77 degrees F (20 and 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Keep Darvon Compound-65 out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Darvon Compound-65. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
